Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Fractyl Health (GUTS) Gains from Sales and Divestitures (2024 - 2025)

Fractyl Health's Gains from Sales and Divestitures history spans 2 years, with the latest figure at $22500.0 for Q4 2025.

For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 96.28% year-over-year to $22500.0, compared with a TTM value of $22500.0 through Dec 2025, down 96.28%, and an annual FY2025 reading of $22500.0, down 96.28% over the prior year.
Gains from Sales and Divestitures for Q4 2025 was $22500.0 at Fractyl Health, down from $604509.0 in the prior quarter.
The five-year high for Gains from Sales and Divestitures was $604509.0 in Q4 2024, with the low at $22500.0 in Q4 2025.